Analyst firms · Citigroup · PTCT
Citigroup PTCT price target and rating history
PTC Therapeutics Inc. (PTCT) · Health Care
Citigroup rates PTC Therapeutics Inc. (PTCT) Buy with a $108 price target, as of its latest action on Jun 9, 2026. It has published 5 rating actions on PTCT since September 2022, including 2 upgrades and 2 downgrades. Across 8 firms with a PTCT price target in the last 12 months, the median target is $94.50. Citigroup's $108 is 14% above that.
- Current rating
- Buy
- Price target
- $108
- Median target, all firms
- $94.50
- Actions on PTCT
- 5
Citigroup price target on PTCT
Every Citigroup rating on PTCT
- Jun 9, 2026
- May 7, 2025
- Oct 27, 2023
- Sep 18, 2023
- Sep 1, 2022
How other firms rate PTCT
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Truist Securities | Hold | $62 | Oct 16, 2026 |
| Leerink Partners | Outperform | $98 | Sep 14, 2026 |
| Citigroup | Buy | $108 | Jun 9, 2026 |
| Jefferies | Buy | $85 | May 27, 2026 |
| TD Cowen | Buy | $90 | May 8, 2026 |
| Raymond James | Outperform | $108 | Apr 10, 2026 |
| Barclays | Overweight | $119 | Jan 28, 2026 |
| RBC Capital Markets | Sector Perform | $91 | Dec 1, 2025 |
Questions about Citigroup and PTCT
- What is Citigroup's price target for PTCT?
- Citigroup's latest stated price target for PTC Therapeutics Inc. (PTCT) is $108, from its action on Jun 9, 2026.
- What is Citigroup's rating on PTCT?
- Citigroup rates PTCT Buy, a bullish rating, as of Jun 9, 2026.
- When did Citigroup last change its view on PTCT?
- On Jun 9, 2026, Citigroup upgrades to Buy from Neutral, price target $108.
- How does Citigroup's PTCT target compare with other analysts?
- Across 8 firms with a PTCT price target in the last 12 months, the median target is $94.50. Citigroup's $108 is 14% above that.
More PTCT rating histories
- Truist Securities3
- Leerink Partners3
- Raymond James5
- RBC Capital Markets3
- BofA Securities3
- Morgan Stanley3
All Citigroup ratingsPTCT news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.